Engineering Amphiphilic Platinum(IV) Prodrugs for Treating Drug Resistant Ovarian Cancer
| dc.contributor.advisor | Zheng, Yaorong | |
| dc.contributor.author | Alqarni, Suha | |
| dc.date.accessioned | 2025-01-01T08:15:58Z | |
| dc.date.issued | 2022-12 | |
| dc.description.abstract | The platinum(IV) prodrug approach is a promising method to develop a replacement for classic platinum-based chemotherapy. The mitochondria-damaging Pt(IV) prodrugs have proven effective against drug-resistant ovarian cancer cells and cancer stem cells, which represent long-standing issues in classic platinum chemotherapy. In this work, we present a comprehensive study on engineering novel amphiphilic Pt(IV) prodrugs as mitochondria-damaging agents. The key findings in this study include: 1). Hydrophobicity of the head group of such prodrugs dictates their cell entry and cytotoxicity; 2). Amphiphilic Pt(IV) prodrugs exhibits superior therapeutic effects compared to cisplatin and overcomes drug resistance in ovarian cancer; 3). Amphiphilic Pt(IV) prodrugs trigger mitochondrial damage. | |
| dc.format.extent | 37 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14154/74551 | |
| dc.language.iso | en_US | |
| dc.publisher | Kent State University | |
| dc.subject | ovarian cancer | |
| dc.subject | cancer drug | |
| dc.subject | cancer drug development | |
| dc.subject | chemistry | |
| dc.subject | biochemistry | |
| dc.subject | platinum(IV) | |
| dc.subject | chemotherapy | |
| dc.subject | platinum-based chemotherapy | |
| dc.title | Engineering Amphiphilic Platinum(IV) Prodrugs for Treating Drug Resistant Ovarian Cancer | |
| dc.type | Thesis | |
| sdl.degree.department | Department of Chemistry and Biochemistry | |
| sdl.degree.discipline | Cancer Drug Development | |
| sdl.degree.grantor | Kent State University | |
| sdl.degree.name | Master of Science |